Introduction
RRR-a-tocopheryl succinate (VES), a derivative of vitamin E, has been demonstrated to inhibit the growth of tumor cells in vitro and in vivo (Qian et al., 1996; Kline and Sanders, 1991; Kline et al., 1995; Schwartz, 1993; and reviewed by Prasad and Edwards-Prasad, 1992) . VES induction of apoptosis in C4-1 cells was documented by morphological analyses of chromatin condensation/fragmentation by¯uorescent microscopic analyses of DAPI (4',6-diamidine-2'-phenylindole dihydrochloride) and TUNEL (terminal transferase-mediated dUTPbiotin nick end labeling of DNA) stained cells,¯ow cytometry analyses of propidium iodide and TUNEL labeled cells and electrophoretic evidence of DNA laddering (Qian et al., 1996) . These studies suggested that c-jun is a VES-inducible gene, since C4-1 cells exhibited increased c-jun mRNA levels from 2 ± 24 h of VES treatment and enhanced c-Jun expression from 6 ± 24 h after treatment (Qian et al., 1996) .
This report analyses VES eects on c-jun mRNA and protein stability, and characterizes the functional role of c-Jun in VES induced apoptosis in C4-1 cells. To determine if c-Jun is critical to VES-induced apoptosis, numbers of apoptotic cells, c-Jun expression and c-Jun DNA binding activity were investigated in: (i) C4-1 cells infected with supjun-1, a dominant, negatively acting mutant form of c-jun, and (ii) C4-1 cells treated with an inhibitor of VES-induced apoptosis; namely, RRR-a-tocopherol. The supJun protein is a transdominant inhibitor of AP-1-mediated transcriptional regulation, as it is missing the transactivation domain but retains its speci®c DNA binding activity and leucine zipper domain (Suzuki et al., 1994) . Since c-jun expression is positively regulated by its own product , the presence of supJun is likely to down-regulate c-Jun expression. Provided that this is the case and that the decrease in c-Jun level corresponds to the decrease of AP-1-DNA complex formation, then the inhibition of apoptosis by supJun is direct evidence of c-Jun involvement in VES induced apoptosis. Additionally, we took advantage of a previous observation that the natural form of vitamine E, RRR-a-tocopherol, inhibits VES-induced apoptosis (Yu et al., 1997a) . If upregulation of c-Jun by VES is required for the activation of the apoptotic program then RRR-a-tocopherol should prevent VESinduced c-Jun upregulation. Our experimental design is based on these considerations.
Results
To better understand the nature of VES induced elevation of c-jun expression, we conducted mRNA and protein stability analyses. Our studies show that the stability of c-jun mRNA in C4-1 cells is not eected by VES treatment (Figure 1a) . Following 16 h of VEStreatment, C4-1 cells exhibited a 4twofold higher level of c-jun mRNA than VEH-treated cells; however, mRNA in both VEH and VES cells were reduced within 0.5 to 1 h following actinomycin D treatment. On the other hand, VES treatment results in a modest enhancement of the stability of c-Jun protein ( Figure  1b ). c-Jun protein levels from VES-treated cells remained stable for 4 h after the beginning of the pulse/chase; whereas, c-Jun protein from VEH-treated control cells is stable up to 1 h ( Figure 1b) .
As an approach to examine the functional role of cJun in VES induced apoptosis we used targeted inhibition of c-Jun by the supjun transdominant mutant. In three separate experiments with three independent preparations of viruses, the C4-1 cells were infected with supjun-1-carrying virus (C4-1-SJ cells) or with control mock virus (C4-1-V cells). The eciency of supjun-1-carrying virus infection of C4-1 cells was determined by indirect immuno¯uorescence using a primary antibody (p27 antibody) to RSV gag protein. Seven days after infection, 100% of the cells showed strong expression of p27 RSV gag protein; whereas, uninfected cells were negative. Infected cells were treated with VES (10 mg/ml) or vehicle control (VEH) on days 4, 8 and 19 post-infection and analysed 48 h later (days 6, 10 and 21 post-infection) for markers of apoptosis. At indicated time points C4-1-V cell cultures exhibited 35 ± 39, 24 ± 34 and 31 ± 34% apoptotic cells, while only 6 ± 18, 13 ± 17 and 16 ± 27% apoptotic cells were found in C4-1-SJ cell cultures (Table 1) . No signs of apoptosis were observed in C4-1-V or C4-1-SJ cells following the control treatment by VEH (succinic acid in ethanol solvent). Thus, supjun infection inhibited VES-induced apoptosis by 54 ± 85, 33 ± 59 and 20 ± 48%, respectively (Table 1) .
The expression of endogenous c-Jun and virusencoded supJun was demonstrated by Western/ECL analyses of nuclear extracts from C4-1-V cells and C4-1-SJ cells 10 days post-infection (Figure 2a and b) . In control cells (C4-1-V) VES treatment resulted in a 3.9 ± 4.1-fold increase of endogenous c-Jun compared to VEH treatment. VES treatment of cells expressing the dominant/negative mutant supJun (C4-1-SJ) resulted in a 1.2 ± 1.9-fold increase in endogenous c-Jun expression in comparison to VEH treated C4-1-SJ cells. However, the supjun infection reduced signi®cantly c-Jun levels in C4-1-SJ cells. For instance, in VES-treated C4-1-SJ cells, the level of c-Jun was 2.0 ± 2.5 times lower than in VES-treated C4-1-V cells (Figure 2a ). Expression of supJun was also aected by VES treatment. In VEStreated C4-1-SJ cells the supJun level was 1.4 ± 1.8 times higher than in VEH treated C4-1-SJ cells ( Figure  2b ). The observed dierences in c-Jun protein levels from nuclear extracts obtained from VEH and VEStreated cells does not seem to re¯ect dierences in extractability of c-Jun protein from normal and apoptotic cell populations since nuclear extracts were taken at 18 h after treatment, a time of low apoptosis for VES (510%) treated cells. Furthermore, Western analyses show that the ratio of wildtype c-Jun as well as supJun remained approximately the same using whole cell extracts and nuclear extracts from the above mentioned cells following VES and VEH treatment (data not shown).
There seems to be a correlation between the level of supJun expression and its protective eect on VESinduced apoptosis in C4-1-SJ cells since in older C4-1-SJ cultures (e.g. 21 days after infection) expressing lower levels of supJun (data not shown) the fraction of apoptotic cells increased (Table 1) . were treated with 10 mg/ml of VES or 4 mg/ml of VEH for 16 h; then, 5 mg/ml of actinomycin D was added. At 0, 0.5, 1, 2 and 3 h after the addition of actinomycin D, total RNA was isolated and hybridized to a 32 P-labeled c-jun cDNA probe by Northern blot analyses. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were determined on the same blot to verify equal loading of lanes. After densitometric scanning of the autoradiogram, c-jun mRNA levels were quanti®ed relative to GADPH expression. Data is representative of two independent experiments. (b) C4-1 cells were treated with 10 mg/ml of VES or 4 mg/ ml of VEH for 16 h. Equal numbers of VES-and VEH-treated cells (1.6610 7 ) were labeled with [ 35 S]methionine for 40 min. After the 40 min labeling, excess unlabeled methionine was added and cells were harvested at 0, 0.5, 1, 2, 3, 4 and 6 h. At the end of each chase period, harvested cells were lysed in RIPA buer. Equal amounts of lysates were precleared with normal rabbit Ig (NR-Ig) and protein A/G agarose followed by immunoprecipitation of c-Jun using an antibody speci®c for c-Jun. Identical immunoprecipitation procedures using normal rabbit Ig served as a negative control. Immunoprecipitates were analysed on 10% SDS-polyacrylamide gels. Data is representative of two independent experiments C4-1-V and C4-1-SJ cells at 5610 5 /ml were treated with 10 mg/ml VES for 2 days, stained with DAPI and examined by¯uorescent microscopy for apoptotic characteristics. Next, nuclear extracts prepared from C4-1-V and C4-1-SJ cells 10 days post-infection, following 18 h treatment with VES or VEH were analysed by electrophoretic mobility shift assay (EMSA) for binding to the AP-1 consensus sequence TGACTCA (Figure 3a) . Nuclear extracts from VES-treated C4-1-V cells exhibited a 2.1 ± 3.6-fold increase in AP-1 complex formation when compared to nuclear extracts from VEH-treated C4-1-V control cells. However, the AP-1 complex formation in extracts from VES-treated C4-1-SJ cells was reduced by 1.4 ± 1.5-fold when compared to VEH treatment. The presence of supJun in C4-1-SJ cells resulted in 2.4 ± 2.6-fold reduction of AP-1 binding activity following VES treatment when compared to VES treated C4-1-V cells. This corresponds to a 2.0 ± 2.5-fold reduction of c-Jun level as detected by Western blot analysis (see Figure 2a) . No signi®cant qualitative changes in the pro®le of protein-DNA binding complexes were observed in analysed extracts, except for the appearance of supJun-DNA complexes in extracts from C4-1-SJ cells (Figure 3a) .
These results indicate that supJun reduces expression of c-Jun, thereby reducing AP-1 binding activity. This conclusion was also con®rmed by supershift analyses (Figure 3a) . The presence of pan-speci®c Jun antibodies in EMSA reactions resulted in signi®cant reduction of AP-1 binding activity and in formation of two and three supershifted DNA-protein complexes in C4-1-V and C4-1-SJ cells, respectively. The presence of c-Jun speci®c antibody in EMSA reactions resulted in the formation of one supershifted DNA-protein complex. Addition of anti-c-Fos antibodies also resulted in a single supershifted complex ( Figure 3a ; arrowheads indicate the positions of antibody retarded AP-1 complexes). Addition of an irrelevant rabbit antibody produced data equivalent to lanes in which no antibody was added (data not shown). These data indicate that c-Jun is a component of the AP-1 complex and c-Jun in AP-1 complexes is elevated by VES treatment and reduced in supJun expressing cells. Therefore, the dierences in Jun levels observed in C4-1-V and C4-1-SJ cells after VES treatment (Figure 2a ) result in dierences in AP-1 binding activity. 
It has been observed that RRR-a-tocopherol (d-a-T) inhibited VES-induced apoptosis. In order to determine
Jun Antibody c-Jun Antibody c-Fos Antibody a b Figure 3 Electrophoretic mobility shift assay of AP-1 binding in nuclear extracts from C4-1-V, C4-1-SJ and C4-1 cells. (a) Nuclear proteins (10 mg) from C4-1-V and C4-1-SJ cells treated with VEH or VES (10 mg/ml) for 18 h were supplemented with either no antibody, irrelevant antibody (data not shown) or panspeci®c anti-Jun, anti-c-Jun, or anti-c-Fos antibodies (1 ± 2 ml), incubated with 32 P-labeled oligonucleotide containing AP-1 consensus (TGACTCA), and subjected to electrophoresis. Speci®city of AP-1 binding was determined by competition assays using 100-fold excess of unlabeled consensus oligo or mutant oligo. Arrowheads indicate the positions of antibody retarded AP-1 complexes. (b) Nuclear proteins (10 mg) from C4-1 cells treated with VEH, 10 mg/ml VES, 200 mg/ml d-a-T, or 10 mg/ml VES+200 mg/ml d-a-T for 18 h were incubated with 32 P DNA and electrophoresed as in (a)
Role of c-Jun in vitamin E succinate induced apoptosis M Qian et al whether this agent can inhibit also VES-promoted inducibility of c-Jun, C4-1 cells were co-treated with VES+d-a-T for 1, 2, and 3 days and subsequently analysed. As shown in Table 2 , VES induced apoptosis was reduced by 75, 65 and 70% following 1, 2, and 3 days co-treatment with d-a-T, respectively. Nuclear extracts from these cells were subjected to Western blot analysis (Figure 2c ). VES-promoted inducibility of c-Jun was reduced by the addition of d-a-T as anticipated.
Gel shift analyses of AP-1 binding activity of nuclear extracts derived from C4-1 cells co-treated with VES+d-a-T showed a 1.6-fold reduction when compared to nuclear extracts from cells treated with VES alone (Figure 3b ). In contrast, no eect of d-a-T treatment on AP-1 binding was detected in comparison with VEH treatment. These data show that RRR-atocopherol which inhibits VES-induced apoptosis, inhibits VES-induced increase in c-Jun level, and reduces AP-1 binding activity. These results con®rm the above conclusion, that c-Jun plays a causal role in VES-induced apoptosis.
To further support this conclusion, we examined the possibility that VES can also induce an AP-1 dependent down-stream gene. Northern blot analyses of total RNA detected vimentin transcripts of 2.2 and 2.5 kb. While basal levels of both vimentin transcripts remained stable throughout the 8 and 12 h periods analysed, both transcripts showed slight increases in VES-treated cells at the 24 h time point in comparison to VEH-treated control cells; namely, 0.28 versus 0.42 for the 2.5 kb transcript and 0.31 versus 0.52 for the 2.2 kb transcript (Figure 4 ). Although extremely modest, the 24 h post VES-treatment increases are real, being consistently observed in three independently repeated experiments.
Discussion
In previous studies we showed that VES treatment of C4-1 cells induced DNA synthesis arrest and apoptosis (Kline et al., 1990; Qian et al., 1996) . The molecular events involved in VES-induced growth inhibition by either DNA synthesis arrest or apoptosis are not understood. Previous studies, involving characterization of VES-induced apoptosis in C4-1 cells, showed VES to elevate levels of c-jun, decrease levels of c-myc, and to have no eect on levels of bcl-2 mRNA expression (Qian et al., 1996) . The inhibitory eects of VES on c-Myc levels were detected as a late event in the apoptotic process, i.e. decreases were not observed until after 24 h of treatment; whereas, elevated levels of c-Jun were detected within 6 h after VES treatment (Qian et al., 1996) .
The apoptotic process has been shown to be complex, involving multiple pathways that have both positive and negative regulators (White, 1996) . As a component of the early response transcription factor AP-1, c-Jun plays a regulatory role in cellular responses to phorbol esters, u.v. radiation, tumor necrosis factor-a, and serum growth factors (McMahon and Monroe, 1992) . The AP-1 binding site is recognized by homodimers and heterodimers of Jun family members and by heterodimers of Jun and Fos. The mutual ratio of these transcription factors modulates expression of target genes (Diamond et al., 1990; Angel and Karin, 1991) . AP-1 transcription factors are postulated to be involved in apoptosis, perhaps by activating putative downstream genes involved in later apoptotic events (McMahon and Monroe, 1992) .
In contrast to the striking increase in c-jun mRNA and protein levels following VES treatment, no change was seen in c-Fos levels determined by Western/ECL and mRNA analyses (data not shown). However, c-fos mRNA and protein levels have been analysed during VES-induced apoptosis in other cell model systems, and no consistent pattern has been observed. For example, levels of c-fos mRNA and protein are downregulated by VES treatment of human MCF-7 breast cancer cells, unchanged by VES treatment of human MDA-MB-435 breast cancer cells and upregulated by VES treatment of murine EL-4 helper T-cells (unpublished data; Yu et al., 1997a) . In contrast, early /ml were cultured with 10 mg/ml VES, 200 mg/ml RRR-a-Tocopherol (d-a-T), or a combination of VES+d-a-T. After 1, 2 and 3 days of treatment, cells were stained with DAPI and examined by¯uorescent microscopy for apoptotic characteristics. ) were treated with 10 mg/ml VES or 4 mg/ml VEH. Total cellular RNA was extracted from VEH-and VES-treated cells at 8, 12 and 24 h after treatment initiation.
32 P-labeled vimentin cDNA probe recognized two vimentin transcripts of 2.2 and 2.5 kb. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were determined on the same blot to verify equal loading of lanes. After densitometric scanning of the autoradiogram, levels of the 2.2 and 2.5 kb vimentin transcripts were quanti®ed relative to GAPDH expression. Data is representative of three independent experiments and sustained upregulation of both c-Jun mRNA and protein levels have been observed in all the above cell model systems following VES-treatment (unpublished data). Thus, our working model is that enhanced and prolonged expression of c-Jun is critical to VESinduced apoptosis in a variety of cell types.
In order to provide more insight on the prolonged elevated levels of c-jun, mRNA and protein stability studies have been conducted. Our data from stability studies of c-jun mRNA show that VES treatment does not enhance the stability of c-jun message. However, cJun protein from VES-treated cells is more stable (4 h) after treatment, in comparison to the VEH-treated (1 h) control cells. Since c-jun mRNA and protein are elevated throughout the experimental time points, the modest enhanced stability of c-Jun protein does not account for the prolonged expression of c-Jun protein.
On going studies in the laboratory show that VES induces a prolonged activation of SAPK/JNK (stressactivated protein kinases/Jun N-terminal domain kinases; unpublished data). It is of interest to these studies to note that prolonged JNK activation has been associated with apoptosis induced by environmental stresses such as ultraviolet C and gamma radiation (Chen et al., 1996) .
To further support our model, we conducted studies on a gene whose expression is known to be regulated by c-Jun in order to determine if it is also aected by VES. Based on the availability of avian cloned genes, we found that the mRNA level of a constitutively expressed AP-1 dependent endogenous gene, vimentin, is reproducibly increased at 24 h after VES treatment of C4-1 cells. In spite of multiple attempts, we were not able to show increased AP-1 mediated transcriptional activity of AP-1-luciferase reporter construct in C4-1 cells after VES treatment. However, we clearly observed ®vefold increases in AP-1 mediated reporter gene expression in MDA-MB-435 breast cancer cells following VES treatment (unpublished data). Cell type speci®c dierences and most likely very low transfection eciency in C4-1 cells may account for the observed discrepancy.
In an eort to determine if c-Jun activation is critical to VES-induced apoptosis, our data from studies using cells expressing supJun, a dominant negative mutant c-Jun (C4-1-SJ cells), and C4-1 cells co-treated with VES+RRR-a-tocopherol (one form of vitamin E shown to inhibit VES-induced apoptosis), support the hypothesis that VES induced apoptosis involves elevated c-Jun protein expression. C4-1-SJ cells exhibited reduced VES initiated apoptosis, reduced endogenous c-Jun levels and reduced AP-1 binding to TGACTCA, the AP-1 consensus sequence. EMSA analyses of nuclear extracts from C4-1-SJ cells showed DNA-banding patterns consistent with supJun homodimer formation and reduced levels of AP-1 binding activity. Bands corresponding to heterodimer c-Jun/ supJun DNA complexes were not observed probably due to instability of such complexes. Nevertheless, supJun might interfere with AP-1 mediated transcription regulation. In our system it seems to inhibit VESinduced activation of c-jun expression.
c-Jun participates in a number of diverse cellular responses, including cell proliferation, dierentiation, response to toxic agents and apoptosis (van Dam et al., 1995; Pertovaara et al., 1989; Angel and Karin, 1991).
The diversity of cellular processes in which c-Jun has been demonstrated to function may re¯ect the ability of c-Jun to associate with itself or other members of the AP-1 (Fos/Jun) and ATF/CREB (activating transcription factor/cAMP response element binding protein) families (Angel and Karin, 1991; Diamond et al., 1990; Deng and Karin, 1993; Hai and Curran, 1991) . Further complexity is derived from a variety of transcriptional regulatory events (phosphorylating kinases/dephosphorylating phosphatases/availability of tissue speci®c cofactors) which are in¯uenced by cell type and environmental stimuli (Deng and Karin, 1993; Pfarr et al., 1994) . Thus, it is likely that c-Jun regulation of gene transcription helps provide the cell with the capability to integrate signals from multiple pathways and determine whether the cell proliferates, undergoes cell cycle arrest, dierentiates or undergoes programmed cell death.
Although the role c-Jun may be playing in VES induced apoptosis in avian C4-1 lymphoid cells is not clear, several studies have implicated a role for Jun in programmed cell death in dierent cell systems. Collotta et al. (1992) showed that lymphoblastoid cell lines deprived of growth factors undergo apoptosis and overexpress c-fos and c-jun mRNA. Antisense oligomers to either c-fos or c-jun inhibited apoptosis induced by deprivation of growth factors in this model system (Collotta et al., 1992) . Studies by Ham et al. (1995) showed that neurons deprived of growth factors undergo apoptosis and express elevated levels of cJun. Furthermore, in these studies, a c-jun dominant negative mutant was able to protect the neurons against the growth factor deprivation induced apoptosis while overexpression of a full length c-Jun protein was sucient to induce apoptosis (Ham et al., 1995) . Studies by Xia et al. (1995) showed that apoptosis induced by withdrawal of nerve growth factor from rat PC-12 pheochromocytoma cells resulted in sustained activation of SAPK/JNK and p38MAPK (mitogenactivated protein kinase also termed mammalian homolog of the yeast HOG1), inhibition of ERKs (extracellular signal-regulated kinases) and sustained activation of c-Jun. Apoptosis induced by environmental stress is associated with SAPK/JNK and activated c-Jun (van Dam et al., 1995; Verheij et al., 1996; Chen et al., 1996) . Both nerve growth factor withdrawal and environmental stress induced apoptosis were inhibited by neutralizing antibodies to c-Jun as well as by introduction of a dominant-negative interfering c-jun mutant (Xia et al., 1995; Verheij et al., 1996) .
The ability of RRR-a-tocopherol to block VESinduced apoptosis, and thereby prevent elevated c-Jun expression and reduce AP-1 binding activity in cotreated cells strengthens the hypothesis that elevated cJun may be involved in VES-induced apoptosis. Unfortunately, the mechanism(s) of action by RRRa-tocopherol, a compound recognized for its potent membrane associated antioxidant activities, in blockages of VES-induced apoptosis are not understood. VES is a succinate ester derivative of RRR-atocopherol, the natural source of vitamin E. VES along with the acetate ester is often used as the vitamin E source in commerical supplements because they are more stable in the presence of oxygen than free tocopherol. Although almost all vitamin E in the blood and tissue is in the unesteri®ed tocopherol form after ingestion of a vitamin E ester, two studies have demonstrated that succinate esters of vitamin E can be taken up by cells directly (Slack and Proulx, 1989; Traber et al., 1988) . It is important to note that VES is not an active antioxidant unless the esteri®cation is reversed by cellular esterases and the free RRR-atocopherol regenerated. In the studies reported here it is unlikely that RRR-a-tocopherol is blocking cellular uptake of VES, since co-treated C4-1 cells still exhibit normal levels of VES-induced DNA synthesis arrest (unpublished data). Also, to date there is no evidence that VES is acting as a prooxidant; namely, no evidence of oxidative damage of DNA measured as formation of 8-hydroxy-2-deoxy-guanosine has been observed in C4-1 cells treated with VES (unpublished data).
Our working model ( Figure 5 ) is that prolonged activation of c-Jun is a critical factor in VES-induced apoptosis; whereas, rapid and transient expression of cJun is involved in the induction of cell proliferation. Additional support for the model comes from studies of human MDA-MB-435 breast cancer cells showing that VES-induced apoptosis is dependent on the induction of biologically active TGF-b (Yu et al., 1997b) , and from studies showing that VES-treated cells express prolonged activated JNK and activated ATF-2 in addition to activated c-Jun (unpublished data). Future studies will address whether or not VES induced sustained upregulation of JNK, and c-Jun heterodimerized with activated ATF-2 are critical events in VES-induced apoptosis.
In summary, the results obtained by two dierent approaches support the hypothesis that VES-induced apoptosis involves elevated levels of c-Jun. Expression of a dominant-negative mutant of c-Jun in C4-1 cells protected the cells against VES-induced apoptosis and reduced AP-1 binding activity. Secondly, an agent capable of protecting cells from VES-induced apoptosis also exhibited the ability to prevent VES-induced elevation of c-Jun and reduced VES-induced increases in AP-1 binding activity. Taken together these studies support a crucial role for c-Jun in VES-induced apoptosis. Based on these studies, our working model is that the sustained elevated levels of activated c-Jun are critical to VES-induced apoptosis.
Materials and methods

Cells and viruses
C4-1 cells (RECC-UTC4-1) are a nonvirus-producing lymphoblastoid cell line obtained from avian reticuloendotheliosis virus transformation of spleen cells from 3-week old SPAFAS chickens (Hoelzer et al., 1980) . C4-1 cells are maintained as suspension cultures in RPMI-1640 medium (HyClone, Logan, UT) supplemented with 5% fetal calf serum (HyClone Laboratories), 2 mM glutamine, 100 mg/ml streptomycin, and 100 IU/ml penicillin (Sigma Chemical, St Louis, MO) at 378C in a humidi®ed atmosphere of 5% CO 2 ± 95% air. Cultures are routinely examined to verify absence of mycoplasma contamination.
To introduce a transdominant negative mutant supjun-1 into the C4-1 cells, we used the replication-competent retrovirus vector, composed of pREP and pDS3 SalI fragments containing 5' and 3' half of the provirus, respectively (Okuno et al., 1991) . The supjun expression vector was generated by insertion of 5' end-truncated jun into BglII site of pDS3 (Suzuki et al., 1994) prior to ligation with pREP SalI fragments. The pREP, pDS3 and psupjun were generous gifts of Dr Hideo Iba (Department of Tumor Virus Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan). The ligated DNAs (2 mg) were transfected into chicken embryo ®broblasts and replication-competent virus stocks were collected from the culture 6 days after transfection. C4-1 cells, in standard media, were infected with viruses carrying supjun (C4-1-SV cells). Control of noninfected cells are referred to as C4-1. The eciency of supjun-1 carrying virus infection of C4-1 cells was determined by indirect immuno¯uorescence using a polyclonal antibody (1 : 1000 dilution) to p27 RSV gag protein (p27; Life Sciences, Inc., St Petersburg, FL). Seven days after infection, cells were attached to coverslips using poly-L-lysine and further treated as described previously (Kralova et al., 1994) .
Actinomycin D chase analyses of mRNA stability
Message stability was determined by modi®cations of procedures described by Lohi et al. (1996) . C4-1 cells were treated with VES (10 mg/ml) [Sigma Chemical; VES is dissolved in absolute ethanol and diluted in cell culture media to a ®nal concentration of 10 mg/ml and 0.1% (v/v) ethanol] or equivalent amounts of succinic acid and ethanol solvent (vehicle, VEH) for 16 h, then 5 mg/ml of antinomycin D (Calbiochem-Novabiochem Corporation, Figure 5 Prolonged elevated levels of c-Jun protein is a critical factor in the induction of apoptosis by VES. This activation of cJun is in contrast to rapid and transient expression of c-Jun which is a well established regulator of cell proliferation. Information provided in parenthesis and dotted lines is based on published data (conversion of latent to biologically active TGF-b, Yu et al., 1997b) and preliminary data (prolonged activation of JNK/SAPK stress signaling pathway and activation of ATF2 transcription factor). In this model, activated c-Jun, via dimerization with itself, other Fos/Jun family members of ATF2 cross family members, signals down-stream events that lead to apoptosis La Jolla, CA) was added, and the cells were incubated for 0.5, 1, 2 and 3 h). At each time point, cells were washed with PBS then lysed for total RNA extraction. The abundance and size of c-jun mRNA was analysed by conventional Northern blot analyses and quantitated by scanning the autoradiograms with a densitometer.
Northern blot analyses
Total cellular RNA was isolated and analysed using established procedures (Sambrook et al., 1989) . Fifteen micrograms of RNA was loaded per lane and fractionated by formaldehyde agarose gel electrophoresis (Sambrook et al., 1989) . Filters were hybridized in the mixture of 10% dextran sulfate, 1 M NaCl, 1% SDS, 10 mg denatured salmon sperm DNA in the presence of radiolabeled probes at 658C. As a probe for avian c-jun we used 1 kb XbaI fragment cut from Rc/RSV-c-jun plasmid (generous gift of Dr P Vogt; Nishimura and Vogt, 1988) . The cDNA probe for avian vimentin was a 0.78 kb XbaI-BamHI fragment excised from pCP vector (generous gift of Dr PL Castagnola; Van De Werken et al., 1993) . As a GAPDH cDNA probe, we used a 1.3 kb EcoRI fragment of human cDNA (purchased from ATCC, Rockville, MD).
Pulse chase experiments and immunoprecipitation
The stability of c-Jun protein was determined by modi®cations of procedures described by Oord et al. (1993) and Sutterluety et al. (1996) . For our studies cells were treated with VES (10 mg/ml) or VEH (4 mg/ml) for 16 h, equal numbers of cells (1. 6610 7 ) were washed with methionine-de®cient RPMI (ICN Pharmaceuticals Inc, Costa Mesa, CA). and incubated in 4 ml of methioninede®cient RPMI containing 5% fetal bovine serum (FBS), 1.65 mCi of 35 S-trans Label methionine (Dupont-New England Nuclear, Wilmington, DE) and VES or VEH for 40 min. [
35 S]methionine containing medium was removed, and cells washed three times with methionine-de®cient RPMI. Regular medium (8 ml) containing ten times more unlabeled methionine than normal (2 mM in place of 0.2 mM) was added to the cells and incubations were continued for 0, 0.5, 1, 2, 3, 4 and 6 h. At the end of each chase period, cells (1 ml) were collected, washed three times in cold PBS, pH 7.4, and lysed in 0.5 ml RIPA buer (10 mM Tris-HCl, pH 8.4, 1% NP40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM DTT) at 48C for 30 min. Lysates were then centrifuged in an Eppendorf microfuge at 13 000 r.p.m. for 10 min at 48C. Equal amounts of protein (500 mg) were incubated with 1 mg of normal rabbit Ig (NRIg) and 20 ml of protein A/G agarose (Oncogene Research Products, Cambridge, MA) for 2 ± 4 h at 48C with continuous rotation. The protein-A/G-agaroseNRIg complex was then pelleted and the precleared lysates incubated with 1 mg of c-Jun antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) or NRIg and 10 ml of protein A/G agarose overnight at 48C with continuous rotation. After three washes with RIPA buer, complexes were eluted from the protein A/G agarose by boiling in SDS sample buer, and analysed on 10% SDS-polyacrylamide gels. Gels were ®xed for 15 min in 30% (v/v) methanol, 10% (v/v) acetic acid, followed by a 30 min treatment with ENLIGHTNING (Dupont, New England Nuclear, Wilmington, DE). Gels were dried and exposed to Kodak BioMax MR ®lm at 7708C.
Apoptosis
C4-1-V and C4-1-SJ cells, at 5610 5 cells/ml in T25¯asks, were treated for 2 days with 10 mg/ml VES or VEH. C4-1 cells were cultured with 10 mg/ml VES, 200 mg/ml RRR-atocopherol (Eastman Kodak, Co, Rochester, NY), or with 10 mg/ml VES+200 mg/ml RRR-a-tocopherol. Following treatments, DNA in intact cells were stained with DAPI (4',6-diamidine-2'-phenylindole dihydrochloride; Boehringer Mannheim, Indianapolis, IN) and examined for apoptotic status using a Zeiss ICM 405 microscope with a 487701 ®lter using procedures previously described (Qian et al., 1996) . Cells exhibiting condensed chromatin and fragmentated nuclei were scored as apoptotic.
Western blot analyses and electrophoretic mobility shift assays (EMSA)
Nuclear extracts from C4-1-V and C4-1-SJ cells were prepared as described previously (Qian et al., 1996) . Nuclear extracts were prepared as described by Goldstone and Lavin (1994) . Cells (1610 7 ) were harvested by centrifugation at 1000 r.p.m. for 5 min at 48C in a benchtop centrifuge, and washed twice in ice-cold PBS. The cell pellets from the ®nal wash were resuspended in 400 ml of ice-cold lysis buer (10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg/ ml each of aprotinin, pepstatin, leupeptin and antipain) and left to swell on ice for 30 min. Next, the suspensions were centrifuged for 30 s in a microfuge and the resulting pellets were suspended in 100 ml of storage buer (10 mM HEPES, pH 7.9, 50 mM KCl, 300 mM NaCl, 1 mM EDTA, 1 mM DTT, 20% glycerol, 1 mM PMSF, 1 mg/ml each of aprotinin, pepstatin, leupeptin and antipain), nuclear proteins were extracted by incubation on ice for 30 min with periodic mixing by vortexing, followed by centrifugation for 10 min at 48C in a microfuge. Aliquots of supernatants were stored at 7808C until used. Immediately prior to use, the protein concentration of each extract was determined using the Bradford protein assay (BioRad), and 100 mg protein from each sample was mixed with an equal volume of 26Laemmli reducing sample buer (Laemmli, 1970) and boiled for 2 min. Samples were analysed by one-dimensional SDS ± PAGE on a 0.75 mm thick discontinuous 4 ± 10 ± 18% step polyacrylamide gel using a Hoefer mini-slab gel electrophoretic unit with 0.1 M Tris, 0.1 M Tricine, 0.1% SDS at cathode buer and 0.2 M Tris, pH 8.9 as anode buer. Samples were electrophoresed at 30 mA for approximately 1.5 h. Molecular weight markers (BioRad) were electrophoresed with each run. Proteins were transferred overnight from the gel onto a nitrocellulose membrane (Schleicher and Schuell #68390) by electroblotting in a Hoefer TE 22 Mighty Small Transphor unit using transfer buer (25 mM Tris, 192 mM glycine, 0.01% SDS and 20% methanol) at 35 volts. Endogenous Jun as well as virus-encoded supJun-1 proteins were visualized by ECL detection system (Amersham) using a rabbit antibody (1 : 1000 dilution) to Jun (this reagent was prepared to amino acids 247 ± 263 which encompass the highly conserved DNA binding domain of mouse c-Jun p39 and is broadly reactive with c-Jun, Jun B and Jun D; Santa Cruz Biotechnology, Inc, Santa Cruz, CA; cat# sc-44). c-Jun was recognized by a cJun speci®c rabbit antibody (1 : 1000 dilution) (Santa Cruz cat# sc-45). c-Fos was recognized by a c-Fos speci®c rabbit antibody (1 : 1000 dilution) (kind gift of Drs Rolf Muller and Martin Funk, Institut fur Molekularbiologie and Tumorforschung, Philipps-Universitat Marburg, Germany). Primary antibodies were detected using horseradish peroxidase (HRP)-labeled goat anti-rabbit antiserum (Jackson Immunoresearch Lab. Inc., West Grove, PA; cat# 111-035-003) as the secondary antibody.
EMSA was performed as previously described (Qian et al., 1996) using the 32 P end-labeled oligonucleotide (5'-CGCTTGATGACTCAGCCGGAA-3'/3-GCGAACTACT-GAGTCGGCCTT-5'; Santa Cruz Biotechnology, Inc) containing AP-1 consensus binding sequence TGACTCA as a probe. The unlabeled oligonucleotide as well as the corresponding oligonucleotide containing the mutant sequence TGACTTG (not recognized by AP-1) were used as competitors. In some experiments, antisera to Jun, c-Jun, cFos or irrelevant antibody control [same antibody reagents as used in the Western/ECL employed at 1 ± 2 mg/reaction mixture] were added to the binding reaction overnight at 48C. The samples were analysed by electrophoresis on a nondenaturing 5% polyacrylamide gel, and shifted bands were detected by autoradiography. Comparisons among levels were determined by densitometric analyses.
Abbreviations C4-1: RECC-UTC4-1 reticuloendotheliosis virus transformed lymphoid cells; C4-1-V: C4-1 cells infected with empty vector, C4-1-SJ: C4-1 cells infected with supjun; daT: RRR-a-tocopherol; DAPI: 4',6-diamidine-2'-phenylindole dihydrochloride; EMSA: electrophoretic mobility shift assay; TUNEL: Terminal transferase-mediated dUTPbiotin nick end labeling; VEH: vehicle, VES: vitamin E succinate (RRR-a-tocopherol succinate).
